Low BTG2 expression correlated with decreased overall survival (Fig. 5a, Table S3 in Additional file 1) and metastasis-free survival (Fig. 5b) of breast cancer patients, indicating that BTG2 is a clinically relevant suppressor of breast tumor progression. The gene discussed is BTG2; the disease is breast neoplasm.